BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 9681080)

  • 21. [Clinical evaluation of DLF, CLF and DFM regimens based on platinum compound plus 5-fluorouracil for treatment of advanced esophageal carcinoma].
    Jiang Y; Qiu XH; Yang YX; Zhang SQ; Chen ZM
    Ai Zheng; 2006 Aug; 25(8):1029-34. PubMed ID: 16965688
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial.
    Ducreux M; Van Cutsem E; Van Laethem JL; Gress TM; Jeziorski K; Rougier P; Wagener T; Anak O; Baron B; Nordlinger B;
    Eur J Cancer; 2005 Feb; 41(3):398-403. PubMed ID: 15691639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II trial of cisplatin, 5-fluorouracil and folinic acid using a weekly 24-h infusion schedule for locally advanced head and neck cancer: a pharmacokinetic and clinical survey.
    Riva C; Lavieille JP; Schmerber S; Cuisnie O; Reyt E
    Int J Oncol; 2000 Sep; 17(3):543-9. PubMed ID: 10938396
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours.
    Ellis PA; Norman A; Hill A; O'Brien ME; Nicolson M; Hickish T; Cunningham D
    Eur J Cancer; 1995 Sep; 31A(10):1594-8. PubMed ID: 7488407
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase II study of LFP therapy (5-FU (5-fluorourasil) continuous infusion (CVI) and Low-dose consecutive (Cisplatin) CDDP) in advanced biliary tract carcinoma.
    Kobayashi K; Tsuji A; Morita S; Horimi T; Shirasaka T; Kanematsu T
    BMC Cancer; 2006 May; 6():121. PubMed ID: 16677397
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer.
    Chen LT; Liu TW; Wu CW; Chung TR; Shiah HS; Jan CM; Liu JM; Whang-Peng J; Chang JY
    Oncology; 2002; 63(3):239-47. PubMed ID: 12381903
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II trial of cisplatin, interferon alpha-2b, doxorubicin, and 5-fluorouracil for biliary tract cancer.
    Patt YZ; Hassan MM; Lozano RD; Waugh KA; Hoque AM; Frome AI; Lahoti S; Ellis L; Vauthey JN; Curley SA; Schnirer II; Raijman I
    Clin Cancer Res; 2001 Nov; 7(11):3375-80. PubMed ID: 11705850
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase I-II trial of the Southern Italy Cooperative Oncology Group (SICOG).
    Caponigro F; Comella P; Rivellini F; Avallone A; Budillon A; Di Gennaro E; Mozzillo N; Ionna F; De Rosa V; Manzione L; Comella G
    Ann Oncol; 2000 May; 11(5):575-80. PubMed ID: 10907951
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer.
    Honecker F; Kollmannsberger C; Quietzsch D; Haag C; Schroeder M; Spott C; Hartmann JT; Baronius W; Hempel V; Kanz L; Bokemeyer C
    Anticancer Drugs; 2002 Jun; 13(5):497-503. PubMed ID: 12045461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mitomycin C, cisplatin, and 5-fluorouracil for advanced and/or recurrent head and neck squamous cell carcinomas.
    Iop A; Cartei G; Vigevani E; Clocchiatti L; Mansutti M; Sibau AM
    Am J Clin Oncol; 1997 Oct; 20(5):515-8. PubMed ID: 9345340
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.).
    Gebbia V; Majello E; Testa A; Pezzella G; Giuseppe S; Giotta F; Riccardi F; Fortunato S; Colucci G; Gebbia N
    Cancer; 1996 Sep; 78(6):1300-7. PubMed ID: 8826954
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cisplatin, 5-fluorouracil, and high-dose oral leucovorin for advanced head and neck cancer.
    Vokes EE; Schilsky RL; Weichselbaum RR; Guaspari A; Guarnieri CM; Whaling SM; Panje WR
    Cancer; 1989 Mar; 63(6 Suppl):1048-53. PubMed ID: 2783881
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemotherapy with vinorelbine, cisplatin and continuous infusion of 5-fluorouracil in locally advanced breast cancer: a promising low-toxic regimen.
    Orlando L; Colleoni M; Curigliano G; Nolè F; Ferretti G; Masci G; Peruzzotti G; Minchella I; Intra M; Veronesi P; Viale G; Goldhirsch A
    Anticancer Res; 2001; 21(6A):4135-9. PubMed ID: 11911307
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of 96-hour infusion fluorouracil plus cisplatin in combination with alpha interferon for patients with advanced squamous cell carcinoma of the head and neck: a Southwest Oncology Group study.
    Hussain M; Benedetti J; Smith RE; Rodriguez GI; Schuller D; Ensley J
    Cancer; 1995 Oct; 76(7):1233-7. PubMed ID: 8630903
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
    Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
    Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase II trial of cisplatin, methotrexate, levofolinic acid, and 5-fluorouracil in the treatment of patients with locally advanced, metastatic squamous cell carcinoma of the head and neck.
    Caponigro F; Comella P; Marcolin P; Russo Spena F; Biglietto M; Cartenì G; De Lucia L; Avallone A; Gravina A; Comella G
    Cancer; 1999 Feb; 85(4):952-9. PubMed ID: 10091775
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
    Hitt R; Hornedo J; Colomer R; Mendiola C; Brandariz A; Sevilla E; Alvarez-Vicent J; Cortés-Funes H
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):50-4. PubMed ID: 8643971
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II study of cisplatin, epirubicin, and continuous-infusion 5-fluorouracil for advanced biliary tract cancer.
    Morizane C; Okada S; Okusaka T; Ueno H; Saisho T
    Oncology; 2003; 64(4):475-6. PubMed ID: 12759549
    [No Abstract]   [Full Text] [Related]  

  • 39. Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type.
    Hasbini A; Mahjoubi R; Fandi A; Chouaki N; Taamma A; Lianes P; Cortès-Funes H; Alonso S; Armand JP; Cvitkovic E; Raymond E
    Ann Oncol; 1999 Apr; 10(4):421-5. PubMed ID: 10370784
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma: a monoinstitutional experience.
    Moretto R; Raimondo L; De Stefano A; Cella CA; Matano E; De Placido S; Carlomagno C
    Anticancer Drugs; 2013 Oct; 24(9):980-5. PubMed ID: 23928570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.